MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Regorafenib Hydrochloride
CAS No. : 835621-07-3
MCE 国际站：Regorafenib Hydrochloride
产品活性：Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) 是一种多靶点抑制剂，靶作用于 VEGFR1/2/3，PDGFRβ，Kit，RET 和 Raf-1，IC50 值分别为 13/4.2/46，22，7，1.5 和 2.5 nM。
研究领域：Protein Tyrosine Kinase/RTK | Autophagy | MAPK/ERK Pathway
作用靶点：VEGFR | Autophagy | PDGFR | Raf | RET
In Vitro: Regorafenib potently inhibits VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with an IC50 of 3 nM. In HAoSMCs, regorafenib inhibits PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of 3 nM. Regorafenib causes a concentration-dependent decrease in Hep3B cell growth, having an IC50 of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells.
In Vivo: Regorafenib effectively inhibits growth of the Colo-205 xenografts in the dose range of 10-100 mg/kg reaching a TGI of 75% at day 14 at the 10 mg/kg dose. In the MDA-MB-231 model, regorafenib is highly efficacious at a dose as low as 3 mg/kg, resulting in a significant TGI of 81%, which increases to 93% at doses of 10 and 30 mg/kg, where tumor stasis is reached.
相关产品：Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Immunology/Inflammation Compound Library | Kinase Inhibitor Library | MAPK Compound Library | Protein Tyrosine Kinase Compound Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Autophagy Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Differentiation Inducing Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Ferroptosis Compound Library | Anti-COVID-19 Compound Library | Orally Active Compound Library | Glutamine Metabolism Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Breast Cancer Compound Library | Anti-Lung Cancer Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Anti-Obesity Compound Library | Angiogenesis-Related Compound Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | EMA-Approved Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Anti-Pulmonary Fibrosis Compound Library | Off-patent Drug Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Cytokine Inhibitors Library | Cell Death Library | Serine/Threonine Kinase Inhibitor Library | Anti-Hematopathy Compound Library | Anti-Ovarian Cancer Compound Library | Multi-Target Compound Library | Bioactive Compound Library Max | Anti-Gastric Cancer Compound Library | Anti-Fibrosis Compound Library | Sorafenib | Lenvatinib | Dabrafenib | Vemurafenib | Bevacizumab | Regorafenib | Imatinib | Semaxinib | Sunitinib | Nintedanib | Cabozantinib | Doramapimod | Ponatinib | Encorafenib | Axitinib | Chloramphenicol | Midostaurin | Pazopanib | PD173074 | Glycine | SB-590885 | Selpercatinib | RMC-7977 | Tanshinone IIA | Fruquintinib | Pralsetinib | SU 5402 | 5Z-7-Oxozeaenol
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
